

1 **Exercise and brain health in patients with coronary artery disease:** 2 **study protocol for the HEART-BRAIN randomized controlled trial**

3 **Angel Toval*¹, Patricio Solis-Urra^{1,2}, Esmée A Bakker^{1,3}, Lucía Sánchez-Aranda¹, Javier**
4 **Fernández-Ortega¹, Carlos Prieto¹, Rosa María Alonso-Cuenca^{1,4}, Alberto González-García⁵,**
5 **Isabel Martín-Fuentes¹, Beatriz Fernandez-Gamez¹, Marcos Olvera-Rojas¹, Andrea Coca-**
6 **Pulido¹, Darío Bellón¹, Alessandro Sclafani¹, Javier Sanchez-Martinez¹, Ricardo Rivera-López⁶,**
7 **Norberto Herrera-Gómez^{1,4}, Rafael Peñafiel-Burkhardt⁶, Víctor López-Espinosa⁶, Sara Corpas-**
8 **Pérez⁴, María Belén García-Ortega⁶, Alejandro Vega-Cordoba⁶, Emilio J. Barranco-Moreno¹,**
9 **Francisco J. Morales-Navarro ¹, Raúl Nieves¹, Alfredo Caro-Rus¹, Francisco J. Amaro-**
10 **Gahete^{7,8,11}, Jose Mora-Gonzalez¹, Sol Vidal-Almela¹, Anna Carlén^{1,9}, Jairo H. Migueles¹, Kirk**
11 **I. Erickson¹⁰, Eduardo Moreno-Escobar^{4,11}, Rocío García-Orta^{6,11}, Irene Esteban-Cornejo^{1,8,11},**
12 **Francisco B. Ortega* ^{1,11,12}**

13 ¹ Department of Physical and Sports Education, Sport and Health University Research Institute (iMUDS), Faculty of Sport
14 Sciences, University of Granada, Spain.

15 ² Faculty of Education and Social Sciences, University Andres Bello, Viña del Mar, Chile.

16 ³ Department of Primary and Community Care, Radboud university medical center, Nijmegen, the Netherlands

17 ⁴ Cardiology Service, San Cecilio Clinical University Hospital, Granada, Spain

18 ⁵ Department of Nursing, Faculty of Health Sciences, University of Granada, Spain

19 ⁶ Cardiology Service, Virgen de Las Nieves University Hospital, Granada, Spain

20 ⁷ Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain

21 ⁸ CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Granada, Spain.

22 ⁹ Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Sciences, Linköping
23 University, Linköping, Sweden

24 ¹⁰ AdventHealth Research Institute, Neuroscience, Orlando, USA

25 ¹¹ Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain

26 ¹² Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

27 * **Correspondence:**

28 Corresponding authors: Francisco B. Ortega and Angel Toval. Department of Physical Education and
29 Sports, Faculty of Sports Science, University of Granada; Carretera de Alfacar, 21. Granada 18071,
30 Spain; +(34) 958 24 66 51, fax: +(34) 958 24 94 28; email: ortegaf@ugr.es and
31 j.angel.toval@gmail.com

32 **Trial Sponsor:** University of Granada; Crtra. Alfacar, 21. Granada 18071, Spain; +(34) 958 24 66 51

33 **Keywords:** ischemic disease, coronary heart disease, cerebral blood flow, cognition, executive
34 function, fitness, HIIT, resistance training

35 **Trial registration:** ClinicalTrials.gov: NCT06214624

38 **ABSTRACT**

39 **Introduction:** Patients with coronary artery disease (CAD), also called coronary heart disease, have a
40 higher risk of developing cognitive impairment and mental health disorders compared to the general
41 population. There is a need to identify effective and sustainable strategies to improve brain health in
42 individuals with CAD, in which physical exercise could play a major role. The overall goal of the
43 HEART-BRAIN randomized controlled trial (RCT) is to investigate the effects of exercise, including
44 different types, on brain health outcomes in patients with CAD, and the underlying mechanisms.

45 **Methods:** This three-arm, single-blinded RCT will include 90 adults with CAD, aged 50-75 years. The
46 participants will be randomized into: 1) control group - usual care (n=30), including periodic medical
47 visits and medication management, 2) aerobic high-intensity interval training (HIIT) (n=30), or 3)
48 aerobic HIIT combined with resistance exercise training (n=30). The intervention will last 12 weeks,
49 offering 3 sessions (45min each) per week to the exercise groups, and the study outcomes will be
50 assessed at baseline and after the intervention. The primary outcome of the study is to determine
51 changes in global and regional cerebral blood flow assessed by magnetic resonance imaging.
52 Secondary outcomes include changes in brain vascularization, cognitive measures (i.e., general
53 cognition, executive function and episodic memory), and cardiorespiratory fitness. Additional health-
54 related outcomes will be evaluated, and several potential mediators and moderators will be investigated
55 (i.e., brain structure and function, cardiovascular and brain-based biomarkers, hemodynamics, physical
56 function, body composition, mental health, and lifestyle behavior).

57 **Conclusions:** The HEART-BRAIN RCT will provide novel insights on how exercise can impact brain
58 health in patients with CAD and the potential mechanisms explaining the heart-brain connection, such
59 as changes in cerebral blood flow. The results might have important clinical implications by increasing
60 the evidence on the effectiveness of exercise-based preventive strategies that could delay cognitive

61 decline in this high-risk CAD population. Our findings will be relevant for patients with CAD,
62 researchers and healthcare providers involved in CAD-related clinical care.

63 1 INTRODUCTION

64 More than 300 million people globally are currently living with coronary artery disease (CAD), also
65 called coronary heart disease, (1), which consists of a narrowing or blockage of the coronary arteries
66 mainly caused by atherosclerosis. CAD is the most prevalent cardiovascular disease and a leading
67 cause of mortality and morbidity worldwide (1-5). CAD incurs a significant economic burden, with
68 annual costs estimated at €77 billion in the EU and \$239.9 billion in the USA (3, 6). Recent studies
69 have shown that individuals with CAD are at high risk of accelerated decline in cognitive and mental
70 health compared to aged-matched adults without CAD, supporting a nexus between the heart and the
71 brain (7-11). Indeed, the cardiovascular risk factors associated with CAD similarly predispose
72 individuals to cerebrovascular disease, in turn affecting their cerebral perfusion. While pharmaceutical
73 therapies have traditionally been the cornerstone of CAD treatment, exercise is an effective non-
74 pharmaceutical intervention for improving cardiometabolic health in these patients (12-15). However,
75 the potential effect of exercise on brain health among individuals with CAD, as well as the mechanisms
76 underlying the heart-brain connection, remain unknown.

77 A key physiological mechanism modulating the heart-brain connection might involve the intricate
78 machinery responsible for supplying blood to the brain. Chronic cerebral hypoperfusion, marked by
79 reduced cerebral blood flow (CBF), impedes the brain's access to vital oxygen and nutrients (9, 16-18).
80 Therefore, a disrupted CBF could play an important role by accelerating cognitive decline and
81 increasing the risk of dementia and mental health disorders in patients with CAD. In turn, exercise
82 could serve as a pivotal factor to enhance CBF, offering a promising non-pharmaceutical adjunct
83 therapy. Limited evidence suggests that exercise may increase CBF and induce brain angiogenesis (i.e.,
84 growth of new capillaries). However, these findings are mainly derived from observational evidence
85 and animal studies (19, 20). These hypotheses need to be tested in randomized controlled trials (RCTs)

86 in humans. The most advanced neuroimaging techniques (particularly in magnetic resonance imaging,
87 MRI) allow non-invasive (no contrast) methods to assess *in vivo* CBF using the Arterial Spin Labelled
88 sequence (ASL-MRI) and cerebral vascularization using magnetic resonance angiography (MRA) (21).
89 These state-of-the-art techniques can provide unique and novel information about the connection of
90 these two possible mechanisms (i.e. changes in CBF and cerebral vascularization) with cognition and
91 mental health.

92 Physical exercise is strongly recommended in the clinical management of patients with CAD to reduce
93 disease progression and the risk of major cardiovascular events (13, 22). However, the mechanisms by
94 which different types and doses of exercise induce a variety of physiological responses are still not
95 fully understood. For instance, modalities such as high-intensity interval training (HIIT) or its
96 combination with resistance training are understudied. HIIT may offer superior health benefits, such
97 as larger improvements in cardiorespiratory fitness, compared to moderate intensity continuous
98 training (MICT) in patients with CAD (8–11). However, it is unknown if HIIT is also superior for
99 improving brain health outcomes. On the other hand, resistance training and the combination of aerobic
100 and resistance training remain understudied, despite recommendations by the World Health
101 Organization (WHO) (23) and the European and American clinical guidelines for CAD management
102 (12) (14, 24), all advocating for the combination of aerobic and resistance training for optimal health
103 benefits (12, 13). Since one of the most documented benefits of exercise is the improvement in
104 cardiorespiratory fitness (25-27), and this marker has been consistently linked to better brain health
105 outcomes (28, 29), cardiorespiratory fitness might serve as a potential mediator of the beneficial effects
106 of exercise on the HEART-BRAIN outcomes.

107 Based on the existing research gaps, we have designed the HEART-BRAIN project, an RCT to
108 investigate the effects of exercise training on brain health outcomes in patients with CAD, including

109 the underlying mechanisms of the heart-brain connection. Herein, we describe the rationale and
110 methodology of the HEART-BRAIN RCT.

111 **1.1 Study objectives**

112 The overall objective of the HEART-BRAIN trial is to investigate the effects of exercise on brain
113 health outcomes in patients with CAD.

114 The primary objective of the study is to investigate the effects of aerobic HIIT and aerobic HIIT plus
115 resistance training compared to usual care (i.e. no exercise training) on global and regional CBF in
116 individuals with CAD.

117 Secondary objectives: to determine the effects of aerobic HIIT, and aerobic HIIT plus resistance
118 training compared to usual care on (i) cerebral vascularization, (ii) executive function and general
119 cognition, and (iii) cardiorespiratory fitness. Additionally, we will investigate the role of potential
120 moderators and mediators (see details in statistical analysis section) on the expected effects.

121 Tertiary objectives: to determine the effects of aerobic HIIT, and aerobic HIIT plus resistance training,
122 compared to usual care on additional outcomes related to cardiovascular and brain health, such as brain
123 structure and function, inflammatory, cardiovascular and brain-based biomarkers, cardiac, vascular and
124 transcranial non-invasive hemodynamics, physical function, body composition, mental health and
125 lifestyle behavior.

126 Our primary hypothesis is that both exercise groups will have a greater increase in CBF compared to
127 the usual care control group, in which HIIT plus resistance training might have a larger effect size than
128 HIIT only.

129

130 2 METHODS AND ANALYSIS

131 2.1 Design and ethics

132 The HEART-BRAIN trial is a single-centered, three-armed, single-blinded RCT, in which 90 adults
133 with CAD, between 50-75 years old, living in Granada (Spain), will be enrolled (**Figure 1**). Participants
134 meeting the eligibility criteria will be randomized into three groups: 1) aerobic HIIT exercise program
135 (n=30), 2) aerobic HIIT plus resistance training exercise program (n=30), and 3) control group - usual
136 care (n=30). The group receiving usual care will be treated as standard care in Spain which includes
137 periodic medical revisions and medication control. The two exercise groups will undertake a 12-week
138 supervised exercise program. All the study outcomes will be assessed at baseline and during the 12-
139 week follow-up. Lifestyle behaviors will also be evaluated at mid-point (6 weeks).

140 Eligible participants will receive written information about the study objectives and design, and will
141 provide informed consent before participation. The trial protocol is in accordance with the principles
142 of the Declaration of Helsinki and was approved by the Research Ethics Board of the Andalusian
143 Health Service (CEIM/CEI Provincial de Granada; #1776-N-21 on December 21st, 2021). The RCT is
144 registered on Clinicaltrials.gov (NCT06214624; submission date: December 22nd, 2023) and the study
145 protocol and statistical analysis plan were uploaded before the last participants were randomized
146 (submission date: January 29th, 2024). The study has been designed following the Standard Protocol
147 Items for Randomized Interventional Trials (SPIRIT) (30, 31) and the SPIRIT-Outcomes 2022
148 Extension (32) (**Supplementary Table 1**). Any significant changes to the protocol will be reported to
149 the trial registry and the Research Ethics Board, which is in line with the SPIRIT guidelines. Moreover,
150 participants in the HEART-BRAIN trial are insured under a social responsibility policy from the
151 University of Granada, which covers ancillary services, post-trial care or compensation if necessary.
152 There are no financial rewards provided to participants for their involvement in the study.

153 **2.2 Recruitment and screening**

154 Participants with CAD will be recruited from two public hospitals in Granada, Spain: the “Hospital
155 Universitario Virgen de las Nieves” and the “Hospital Universitario Clínico San Cecilio”. Recruitment
156 started in May 2022, and we plan to enroll a minimum of 90 patients, aged 50-75, with stable CAD
157 (phase III) proven by invasive coronary angiography or CT with at least one coronary stenosis with >
158 50% luminal reduction. A complete list of eligibility criteria is presented in **Table 1**. Eligible patients
159 will be screened by the clinical and research team in three steps (**Figure 1**): 1) screening by the
160 clinicians of the research team (i.e., based on clinical history); 2) screening based on a phone call
161 conducted by the research team; and 3) screening during the baseline assessments including the
162 cardiopulmonary exercise test (CPET) and echocardiography. Participants will be recruited in waves,
163 with 10 to 20 people in each wave, throughout the year. In accordance with the CONSORT flow
164 diagram (33), we will note the number of patients that were assessed for eligibility by the clinical and
165 research team, the number of excluded patients (indicating reason for exclusion) during the enrollment
166 phase and the number of randomized participants. For the allocation, the number of participants
167 allocated to the intervention groups and the number of participants who received the intervention (with
168 reasons for nonadherence to the allocated arm) will be noted. The number of participants who were
169 lost to follow-up (dropouts) and who discontinued the intervention (including reasons) will be reported.
170 Finally, the number of participants that were included in the analyses using the intention-to-treat and
171 per-protocol databases will be described together with the reasons for the exclusion from the analytic
172 database.

173 **2.3 Randomization**

174 Randomization will occur on a rolling basis and only after the completion of all baseline assessments,
175 through REDCap Software (34). Participants will be randomized using a 1:1:1 ratio and stratified by

176 age (<65 years or \geq 65 years) and sex (female or male). To ensure adequate allocation concealment,
177 this procedure will be carried out by a blinded external researcher (Dr. Cabanas-Sanchez, Autonomous
178 University of Madrid, Spain).

179 **2.4 Blinding**

180 Participants cannot be blinded due to the nature of the interventions, as they will inevitably become
181 aware of their group allocation. Nonetheless, the principal investigator (PI) and the research team
182 members participating in the post-intervention evaluations (who are not involved in monitoring the
183 exercise sessions) will be blinded to the group assignments. Unblinding will only occur in case of an
184 unexpected adverse event involving a participant and will only be done by the PI or a physician.

185 **2.5 Interventions**

186 A detailed and broader description of the program will be further extended in the Consensus on
187 Exercise Reporting Template (CERT) study protocol of the HEART-BRAIN trial (*manuscript in*
188 *preparation*). Briefly, participants will be randomized to one of the following three groups:

189 Aerobic high-intensity interval training (HIIT). 12-week duration, 3 times/week. This consists of a 4x4
190 HIIT (preferably on the treadmill): 4 intervals of 4 minutes at high intensity (85-95% of HRmax),
191 interspersed with 3 intervals of 3 minutes of active resting at \sim 70% of HRmax. All sessions include 10
192 minutes of warm-up and 10 minutes of cool-down, resulting in a total session time of 45 minutes.
193 During the familiarization period (first two weeks), participants will progress from moderate-intensity
194 training to the target HIIT.

195 Aerobic HIIT plus resistance training. 12-week duration, 3 times/week. The aerobic part consists of a
196 3x4 HIIT (preferably on treadmill), with 3 intervals of 4 minutes at high intensity (85-95% of HRmax),

197 interspersed with 2 intervals of 3 minutes of active resting (~70% of HRmax). The resistance part
198 consists of 2 rounds of an 8-exercise circuit (a combination of upper and lower body exercises using
199 elastic bands and body weight) with a ratio of 20 seconds of effort followed by 40 seconds of resting.
200 Sessions will have 5 minutes of warm-up on the treadmill and 5 minutes of cool-down walking around
201 the gym, for a total session time of 45 minutes.

202 Control group – usual care. The control group will be treated as usual in outpatient Phase III, which in
203 Spain includes periodic medical revisions where the clinician may provide patients with lifestyle and
204 clinical advice (e.g., inform about exercise limitations, if any, and nutrition recommendations, stress
205 management) and medication control. In addition, in the control group, we will apply the wait-list
206 strategy, offering participants the HIIT supervised program described above, once data collection for
207 pre- and post-intervention assessments is completed.

208 All intervention groups will receive the same usual care. The HIIT program and the HIIT part of the
209 combined HIIT plus resistance training program have been designed based on the guidelines for the
210 delivery and monitoring of HIIT in clinical populations (35) and meet the aerobic recommendations of
211 the WHO guidelines, as it surpasses the minimum of 75 minutes of vigorous intensity or 150 minutes
212 of moderate intensity per week, or a combination of them (23). The combined HIIT plus resistance
213 training program meets the aerobic and resistance components of the WHO recommendations, as it has
214 3 sessions of resistance training per week while WHO guidelines recommend at least 2 sessions
215 involving major muscle groups. Both exercise programs have been designed to provide an estimated
216 isocaloric workload (same energy expenditure) in terms of intensity and duration.

217 Exercise programs will take place in the Sport and Health University Research Institute (iMUDS) at
218 the University of Granada. Accredited expert trainers with a BSc degree in sports sciences will lead all

219 supervised sessions with a ratio of 1:1 (one trainer, one participant). Exceptionally (e.g., scheduling
220 conflicts), a ratio of 1:2 will be used.

221 Both training programs are individually tailored. Exercise prescription, monitoring, and decisions for
222 progression will be based on the percentage of HRmax and the 10-point Borg Rating of Perceived
223 Exertion scale (RPE) (36). HRmax will be determined during the CPET with electrocardiogram (ECG)
224 and gas exchange analyzer performed at baseline (see section 2.3.2). Furthermore, symptoms and blood
225 pressure will be monitored before, during, and after the exercise sessions. Participants taking beta-
226 blocker medications often have a blunted HR response (35), which could also affect the HRmax
227 obtained in the CEPT. Thus, while the HRmax will be used as a reference for exercise intensity,
228 participants will be encouraged to learn and use RPE. This indicator will be used as a reference in case
229 of discordance between HR and RPE targets. In addition, the trainers will use their judgment to adapt
230 the intensity, particularly during the resistance training, because RPE might be less reliable in
231 inexperienced participants (35).

232 **2.6 Adherence, attendance, and compliance**

233 Since the term adherence has been used with different meanings in the literature, in our study we will
234 refer to two concepts more unequivocally used: attendance and compliance. Attendance will be defined
235 as the percentage of sessions attended by the participant (recorded by the trainers) divided by the
236 number of exercise sessions offered (12 weeks x 3 sessions/week = 36, yet holidays and logistic reasons
237 may lead to slight deviations among waves and participants). Compliance will be defined as the
238 percentage of sessions in which the specified amount of time (i.e., HIIT 6.5 min and HIIT plus
239 resistance training 4.5 min) is spent within the target HR intensity, divided by the number of exercise
240 sessions with valid data (e.g., sessions with technical issues of the HR bands will be excluded). The
241 familiarization phase (i.e., the first two weeks of the exercise intervention) will not be considered for

242 the compliance calculation. The amount of time, i.e., HIIT 6.5 min; HIIT plus resistance training 4.5
243 min, in the target HR intensity is based on the exercise protocol and the guidelines for HIIT prescription
244 and monitoring in clinical populations (35): “for the first high-intensity interval, allow the entire 4-
245 minute period to reach the HR target zone, for subsequent high intensity intervals (i.e., 2nd, 3rd, and/or
246 4th), allow 2-minutes (halfway) to reach the HR target zone”.

247 All protocol deviations will be recorded and reported (e.g., change in pre-defined inclusion/exclusion
248 criteria, baseline and post assessments, data cleaning/processing).

249 **2.7 Safety and adverse events**

250 Although HIIT has been shown to be low risk in patients with CAD (37-39), the safety of our
251 participants is the highest priority in the study. For these purposes, we followed the guidelines for using
252 HIIT in clinical populations and have applied in our study the recommended exclusion criteria (35).
253 Further, CPET together with cardiac and vascular ultrasound will be performed at baseline and serve
254 as a clinical assessment to confirm the absence of underlying conditions that contraindicate exercise.

255 The center where the exercise training sessions will be delivered (iMUDS) is located in the Hospital
256 area next to the emergency unit (200 meters) and the ambulance unit (600 meters). A trained allied
257 health professional (nurse or physician) will be present in the center during the training sessions to
258 guarantee a timely response in case of an adverse event. The center has a fully equipped trolley with a
259 first aid kit and automatic defibrillator and obtained the Andalusian Certification of “Cardioprotected
260 Center” (Decreto 22/2012 of February 14th). Furthermore, all members of the project team will receive
261 certified training courses in cardiopulmonary resuscitation and the use of a semi-automatic
262 defibrillator.

263 In case of an adverse event, we will follow the protocol recommended by the Spanish Council of
264 Cardiopulmonary Resuscitation (CERCP). The number and reasons for adverse events (e.g., falls,
265 injuries, musculoskeletal problems, major cardiovascular events, and any other events potentially
266 related to the implementation of the trial protocol) occurring at any time during the study will be
267 collected, reported, and separately described for each study arm. The participants allocated to the
268 exercise group will be able to communicate any adverse events during their regular contact with the
269 project team (i.e., 3 sessions/week), whereas those allocated to usual care will be asked to report any
270 adverse event promptly, and will be called by phone for these regards at weeks 3, 9 and 12. Adverse
271 events will be described in a table in the main HEART-BRAIN manuscript. Each adverse event will
272 be clinically ascertained to judge whether the event was due to exercise in the corresponding study arm
273 using an adverse event algorithm (i.e., Liverpool Causality Assessment Tool) (40) and recorded
274 according to the Common Terminology Criteria for Adverse Events, (CTCAE) (41) by an experienced
275 cardiologist (EME) after discussion and consensus with the rest of the cardiologists involved in the
276 project.

277 **2.8 Outcomes**

278 The primary, secondary, and additional outcomes, the assessment instruments, and the data collection
279 time points are summarized in **Table 2**. All outcome-related measures, data processing, and statistical
280 analyses will be performed by staff blinded to the intervention assignment.

281 **2.8.1. Primary Outcome Measures:**

282 Change in cerebral blood flow (timepoint: baseline and 12-weeks): CBF (mL/100 g/min) will be
283 measured using the MRI technique of pseudo-continuous arterial spin labeling (pCASL) (42, 43). We

284 will analyze both global and regional CBF, as determined by voxel-wise analysis to measure local
285 perfusion (acquisition parameters in **Table 3**).

286 **2.8.2 Secondary Outcome Measures:**

287 Change in cerebral vascularization (baseline to 12 weeks): Cerebral vascularization will be measured
288 using the time-of-flight-magnetic resonance angiography (TOF-MRA). This sequence allows imaging
289 flow within vessels revealing the cerebrovascular anatomy without the need to administer contrast.
290 Thus, the analysis of TOF-MRA provides the number, distribution, and morphology of intracranial
291 vessels (acquisition parameters in **Table 3**).

292 Change in cognitive outcomes (baseline to 12 weeks): A comprehensive neuropsychological battery
293 will assess several domains of cognition (**Table 4**). General cognition will be assessed by the Montreal
294 Cognitive Assessment (MoCA) test (44). Additionally, the battery includes paper-and-pencil tests
295 (Trail making test (45) and Digit Symbol Substitution Test (46)), National Institutes of Health (NIH)
296 Toolbox tests (Dimensional Change Card Sort Test, Flanker Test, Picture Sequence Memory Test, and
297 List Sort Working Memory Test) (47) and a programmed test in E-prime software (Spatial Working
298 Memory Test) (48). Detailed information about the cognitive tests has been previously described (49).
299 The cognitive indicators will be transformed into standardized z-scores by calculating the difference
300 between each individual raw score and the group average score at baseline, and then dividing by the
301 standard deviation at baseline. We will determine the effects of the interventions on the cognitive
302 outcomes (e.g., general cognition, cognitive flexibility, inhibition control, working memory,
303 processing speed and episodic memory). To guarantee reliable evaluations, all paper-and-pencil tests
304 will be independently scored by two trained evaluators, with any discrepancies resolved through mutual
305 agreement.

306 Change in cardiorespiratory fitness (baseline to 12 weeks). Cardiorespiratory fitness will be assessed
307 by a standardized ramp CPET to exhaustion on a treadmill (h/p/cosmos, Nussdorf, Germany), in
308 accordance with the American College of Sports Medicine Guidelines (50). We decided to use a ramp
309 protocol with small increments, and opted for a standardized, instead of individualized, protocol to be
310 able to compare the time-to-exhaustion (test duration, excluding warm-up) between participants as an
311 additional indicator of exercise capacity and cardiorespiratory fitness, in addition to the peak oxygen
312 uptake. CPET will be carried out by trained staff and under the supervision of a physician. The protocol
313 begins with a 3-minute warm-up phase, during which the speed gradually increases to 4.8 km/h.
314 Following this, the slope will be increased by 1% every 30 seconds until exhaustion or any other
315 indication for test cessation (50), followed by a 3-minute recovery phase. This ramp protocol equates
316 the 3-min increment Bruce tests, as indicated in the American College of Sports Medicine Guidelines
317 (50). The respiratory exchange will be monitored with a dilution flow system (Omincal, Maastricht
318 Instruments, Maastricht, the Netherlands), generating output data at 5-second intervals. A 12-lead
319 electrocardiogram (AMEDTEC ECGpro, GmbH, Aue, Germany) will be continuously monitored by a
320 physician during the test. Heart rate will also be registered with a Polar H10 monitor (including chest
321 band and watch). Systolic and diastolic blood pressures will be measured with an automatic
322 sphygmomanometer (Tango M2; SunTech Medical Inc., NC, USA) every 3 minutes during exercise,
323 and after 3 and 5 minutes of recovery. The RPE will be asked every 3 minutes during the test (51).
324 Peak oxygen uptake (Peak $\dot{V}O_2$) will be defined as the highest rolling 30-second average during the
325 test. Since the heart rate response might be blunted due to beta-blockers and the oxygen uptake plateau
326 is not always observed, staff will note whether participants reach a respiratory exchange ratio (RER)
327 of 1.1 or higher, as RER is one of the most robust indicators of maximal effort in these patients.

328

329

330 **2.8.3 Other Outcome Measures:**

331 **Brain structure and function**

332 CBF (primary outcome), cerebral vascularization (secondary outcome), along with other brain
333 structure and function outcomes will be assessed by MRI at the Mind, Brain and Behavior Research
334 Centre (CIMCYC) at the University of Granada. A Siemens Magnetom PRISMA Fit 3T scanner with
335 a 64-channel head coil will be used. **Table 3** shows the imaging sequences that will be performed for
336 each participant in acquisition order. Participants will be asked to wear comfortable clothing, MRI
337 eligibility criteria will be checked (e.g., not having metallic implants or claustrophobia), and
338 participants will provide additional informed consent specifically for MRI scans. When doubts exist
339 about the compatibility of certain implants, an experienced radiologist will check the composition and
340 material of the implant and inform about the compatibility with MRI before the scanning takes place.
341 Standard MRI sequences will be conducted for approximately 60 minutes. A radiologist will review
342 structural sequences to detect any incidental findings. If any of them are discovered, the radiologist
343 will communicate with the participant for further examination. Besides CBF and cerebral
344 vascularization, the following brain MRI outcomes will be examined (acquisition parameters are
345 shown in **Table 3**):

346 Change in blood-brain barrier (BBB) permeability (baseline and 12 weeks). BBB permeability will be
347 assessed by a recently developed neuroimaging technique that measures water exchange across the
348 BBB using 3D diffusion-prepared arterial spin-labelled perfusion MRI (52).

349 Change in brain morphology (baseline and 12 weeks). MRI will measure brain morphology including
350 volume, area, cortical thickness, and shapes by a T1-weighted MPRAGE (Magnetization Prepared
351 Rapid Gradient Echo) structural sequence.

352 Change in white matter structure (baseline and 12 weeks). MRI will measure white matter
353 microstructure by a diffusion-weighted acquisition sequence.

354 Change in brain function (baseline and 12 weeks). MRI will measure brain function during resting state
355 and measures of brain activity and connectivity will be calculated.

356 **Biological samples**

357 The HEART-BRAIN trial aims to examine various biomarkers by the analysis of blood, saliva, and
358 fecal samples. A trained nurse will collect blood samples from participants under fasting conditions
359 (08:00 to 10:00 a.m.) at the Virgen de las Nieves University Hospital. For post-assessments, blood
360 extraction will be done within the first 3-5 days after the last training session. Briefly, three
361 ethylenediaminetetraacetic acid (EDTA) tubes, two citrate tubes, two serum tubes, and one PAXGENE
362 tube will be collected corresponding to a total of approximately 30 ml of blood per participant visit.
363 Part of the blood samples obtained from each participant will be processed directly at the Hospital (1
364 EDTA, 1 citrate, and 1 serum tube), and the remaining samples will be aliquoted and stored at -80°C
365 for later studies. Saliva samples will be collected into sterilized plastic containers and aliquoted into
366 1.5mL Eppendorf. Fecal samples will also be collected under standardized conditions using sterile
367 plastic containers and stored at -80°C. **Table 5** outlines the specifications of the samples, initial
368 analyses, and preliminary analysis plans. Nevertheless, samples will be analyzed using the best
369 available methods at the time of processing. Blood analyses will cover conventional biochemical
370 measurements, cardiovascular, brain-peripheral, and inflammatory biomarkers, telomere length, and
371 genetic analysis. Saliva and fecal samples will undergo metagenomic analysis to study the microbiome.
372 Some of the analyses will be conducted as additional funding is obtained. Briefly, the main outcomes
373 planned from biological samples include:

374 Change in cardiovascular biomarkers (baseline and 12 weeks). Blood samples will be used to determine
375 concentrations of cardiovascular biomarkers including glucose, insulin, triglycerides, high-density
376 lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol.

377 Change in brain-peripheral biomarkers (baseline and 12 weeks). Blood and saliva samples will be used
378 to determine the concentration of peripheral brain biomarkers such as brain-derived neurotrophic factor
379 (BDNF), vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), cathepsin
380 B (CTSB), amyloid and tau protein levels, as well as novel neurodegenerative biomarkers based on
381 new evidence available at the time of the analysis.

382 Change in inflammatory biomarkers (baseline and 12 weeks). Blood samples will be used to determine
383 concentrations of inflammatory peripheral biomarkers such as tumor necrosis factor-alpha (TNF-
384 alpha), interleukins, and both traditional and high-sensitivity C-reactive proteins.

385 Change in gene expression and epigenetics (baseline and 12 weeks). Blood samples will be stored for
386 epigenetic and gene expression changes.

387 Change in oral and gut microbiota (baseline and 12 weeks). Saliva and fecal samples will be used to
388 determine oral and gut microbiota including the most representative phyla (i.e., firmicutes,
389 Bacteroidetes, and proteobacteria).

390 **Hemodynamics**

391 Hemodynamic changes (baseline and 12 weeks). Non-invasive hemodynamic parameters will be
392 measured using ultrasound (Vivid E95, GE Healthcare) at three levels: 1) vascular (main carotid artery
393 and vertebral artery, with measurements of intima-media thickness, flow, and wall strain, as well as
394 registration of presence of atherosclerotic plaques), 2) cardiac (i.e., cardiac dimensions and volumes,

395 systolic and diastolic function such as ejection fraction, strain deformation, and myocardial work), and
396 3) transcranial (i.e., systolic and diastolic flow velocity in the middle cerebral artery). Image acquisition
397 and analysis will be carried out by cardiologists with expertise in ultrasonography.

398 Change in blood pressure (baseline and 12 weeks). Resting systolic and diastolic blood pressure will
399 be assessed by a validated automated blood pressure monitor (Omron M3, Intellisense, OMRON
400 Healthcare Europe, Spain) in the sitting position after 5 minutes of rest and with the left arm resting on
401 a table at heart level. Three readings will be collected with 2-minute intervals in between. Blood
402 pressure will be calculated as the average of the last two blood pressure readings (53).

403 Change in arterial stiffness (baseline and 12 weeks). Arterial stiffness will be assessed using the pulse
404 wave analysis and carotid-femoral pulse wave velocity (aortic-PWV) by applanation tonometry
405 determined by the SphygmoCor® XCEL PWA/PWV (AtCor Medical, Sydney, Australia).

406 **Physical functioning and body composition**

407 Additional physical function and body composition outcomes will include:

408 Change in physical function and fitness (baseline and 12 weeks). The Senior Fitness Test, including
409 the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery
410 assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54).
411 Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and
412 overall fitness) will be assessed using the International Fitness Scale (IFIS) (55). In addition, muscular
413 strength will be measured with a combination of some of the Senior Fitness Test and handgrip strength
414 test. In brief, each participant will be encouraged to perform the maximal isometric force twice with
415 each hand using a hand dynamometer (TKK 5101 Grip D, Takey, Tokyo Japan). The maximum value
416 of each hand will be taken and averaged in kilograms (kg) as an indicator of upper-body muscular

417 strength. Lower body muscular strength will be assessed using the chair stand test (number of
418 repetitions). Upper body muscular strength will be assessed using the arm curl test (number of
419 repetitions). Perceived strength will be assessed using a single item from the IFIS (55).

420 Change in body composition (Baseline and 12 weeks). Body mass index (BMI, kg/m²) will be
421 computed from height and weight measured with SECA instruments following standardized
422 procedures. Body composition (i.e., lean mass, kg, fat mass, kg, and bone mineral content and density,
423 z-score) will be assessed using a dual-energy x-ray absorptiometer and a TANITA's Bioelectrical
424 Impedance Analysis (TANITA MC-980MA-N plus, Amsterdam, the Netherlands). We will also
425 conduct MRI of the abdominal region to obtain information on overall visceral adipose tissue, specific-
426 organ adipose tissue, and subcutaneous abdominal adiposity.

427 **Mental health and lifestyle behaviors**

428 A battery of questionnaires will be administered to evaluate the following dimensions in relation to
429 mental health and lifestyle behavior:

430 Change in depressive symptoms (baseline and 12 weeks) will be assessed using the Global
431 Deterioration Scale (56), and the Hospital Anxiety and Depression Scale (HADS) (57); change in
432 anxiety symptoms (baseline and 12 weeks) will be assessed using the HADS questionnaire (57); change
433 in stress (baseline and 12 weeks) will be assessed using the Perceived Stress Scale (58); change in
434 loneliness (baseline and 12 weeks) will be assessed using the UCLA Loneliness Scale (59); change in
435 self-esteem (baseline and 12 weeks) will be assessed using the Rosenberg Self-Esteem Scale (60);
436 change in social support (baseline and 12 weeks) will be assessed using the Social Provisions Scale
437 (61).

438 Change in health-related quality of life (baseline and 12 weeks) will be assessed using the SF-36 form
439 (62), which provides an 8-scale profile of functional health and well-being scores (i.e., physical
440 functioning; role limitations due to physical problems; bodily pain; general health perceptions;
441 energy/vitality; social functioning; role limitations due to emotional problems; and mental health) as
442 well as psychometrically-based Physical Component Score (PCS) and Mental Component Score
443 (MCS).

444 Change in physical activity and sedentary behaviors (baseline, 6 and 12 weeks). Physical activity and
445 sedentary behavior will be measured using the accelerometer Axivity AX at baseline and 6-weeks. The
446 accelerometer will be attached to the non-dominant wrist for 9 consecutive days, the sampling
447 frequency will be set at 100 Hz, and the accelerometer raw data processing will be conducted using
448 open-source software tools to ensure transparency and replicability of the methods (63). Additionally,
449 participants will complete the short version self-reported International Physical Activity
450 Questionnaire(64) at baseline and 12 weeks.

451 Change in duration and sleep quality (baseline and 6 weeks). Sleep duration (hours/night) will be
452 computed from the accelerometer Axivity AX and diaries, and an open-source software will be used
453 to process the raw data recordings (63). In addition, participants will complete a single-item question
454 on usual sleep duration. Sleep quality (e.g. sleep regularity, sleep efficiency, latency, number and total
455 time of waking up after sleep onset) will also be assessed using the accelerometer Axivity AX.

456 Change in diet behaviors (baseline, 6 and 12 weeks). Diet behaviors will be self-reported using the 14-
457 item Questionnaire of Mediterranean Diet Adherence (PREDIMED-14) with an additional question for
458 supplement intake.

459 Additional variables related to health, lifestyle and genotype will be measured for descriptive purposes,
460 for covariate adjustment in the analyses when necessary or for interaction with the intervention effects.
461 Examples include biological sex, ethnicity, educational level, smoking habits, alcohol consumption,
462 medication, comorbidities (e.g., dyslipidemia, hypertension, or type 2 diabetes), family history of
463 dementia, handedness, and COVID-19 history. Additionally, genotyping at baseline will be conducted
464 for well-known Single Nucleotide Polymorphisms (SNP) for brain health, such as Apolipoprotein E
465 (APOE) and BDNF genotypes, and additional relevant SNPs based on an updated literature search.
466 The genotyping analysis is conducted to test gene-exercise interaction as we have done in previous
467 RCTs (49).

468 **2.9 Sample size and statistical analysis**

469 A detailed description of the statistical analysis plan, including a sample size calculation, for the
470 HEART-BRAIN trial has been pre-registered and published on Clinicaltrials.gov (NCT06214624;
471 submission date: January, 2024).

472 **2.9.1 Sample size**

473 The HEART-BRAIN project has been designed to detect a low-to-medium size change (i.e. effect size
474 Cohen $d=0.35$) with an alpha of 0.05 and beta of 0.2 (power 0.8). The trial has been powered for a 7%
475 dropout during the intervention (based on our previous RCTs (49)). Thus, the estimated sample size,
476 for repeated-measures ANOVA using G*Power (version 3.1.9.7), was 90 participants (30 in each study
477 arm).

478 **2.9.2 Framework and timing**

479 A superiority hypothesis testing framework will be used. In the main analyses, we will compare
480 whether both exercise interventions (HIIT only or HIIT plus resistance training) are superior to usual
481 care (no exercise training). The final analyses will be performed after collecting and processing the
482 data of the primary and secondary outcomes. The time points for data collection of each outcome are
483 explained in section 2.4.

484 **2.9.3 Statistical interim analyses and stopping guidance**

485 No pre-specified interim analyses will be performed, and therefore, a stopping guidance is not
486 applicable. Basic analyses (not including the primary outcome) have been performed as required by
487 the final report for the funding agencies, after completion of the first 58 participants. The basic analyses
488 have been performed by a researcher who is not involved in data collection (EAB). The results of the
489 basic analyses have not been discussed with other members of the research team involved in the
490 evaluations or interventions to avoid any bias during the implementation of the study, data collection
491 or processing. These basic analyses have not led to any protocol deviations.

492 **2.9.4 Brief description of the primary and secondary analyses**

493 The main analyses will consist of the intention-to-treat analyses for the primary and secondary
494 outcomes using a constrained baseline (meaning baseline adjusted) linear mixed model, which
495 accounts for baseline differences among the study groups. The model will include fixed effects for time
496 (two levels) and treatment (three levels) as well as the unique participant identifier as a random effect.
497 If the global test of significance indicates between-group differences, pairwise comparisons will be
498 explored. Although no adjustments for multiplicity will be performed, family-wise type 1 error rate on
499 the primary outcome will be retained by using a hierarchical analytic approach. The prespecified

500 hierarchical hypotheses will be tested using the prespecified sequence: HIIT plus resistance training
501 versus usual care, HIIT versus usual care, and HIIT plus resistance training versus HIIT. No additional
502 adjustments for covariates will be made (except for baseline adjustments of the outcome). The main
503 statistical analyses will be performed by an independent researcher (EAB), who is not involved in the
504 recruitment, evaluations, and interventions, and who will be blinded to treatment allocation by coding
505 the intervention arms (e.g., A, B, C). The same approach will be applied to secondary and tertiary
506 outcomes.

507 **2.9.5 Moderation, mediation, and other secondary analyses**

508 Although the RCT is not powered for subgroup analyses, we will perform moderation analyses by
509 exploratory subgroup analyses for age, sex, education level, baseline level of the study outcome
510 (stratified on the median), and APOE genotype. Likewise, we plan to explore potential mechanisms
511 driving effects on outcomes. For example, we will run a formal mediation analysis to test whether
512 changes in cardiorespiratory fitness explain exercise-derived changes in brain and cognitive outcomes,
513 and whether changes in CBF or vascularization mediate exercise-derived changes in cognitive
514 outcomes.

515 **2.9.6 Confidence intervals and P values**

516 All statistical tests will be two-tailed. P for significance will be set at 0.05 and 95% confidence intervals
517 will be estimated. No adjustments for multiplicity will be made as multiplicity adjustments may be of
518 lesser importance in the case of distinct treatment arms (65). Since only one primary outcome has been
519 defined, other outcomes do not require adjustment for multiple testing. However, we will include a
520 hierarchical analytic approach for the exercise interventions tested and the primary outcome.

521 **2.9.7 Analysis populations**

522 We plan to use two approaches for the statistical analyses:

523 1. Intention-to-treat (main analysis): This will be used for our primary analyses and includes all
524 randomized participants. With this approach, all randomized participants are included in the analysis,
525 based on the groups to which they were initially randomly assigned to. This implies that some
526 participants will have valid data at both time points, while some might have missing data at baseline
527 or post-intervention assessment, which is sometimes named as “available-case intention-to-treat”.

528 2. Per-protocol and additional sensitivity analyses: This dataset will be used for our secondary analyses
529 and includes all participants with $\geq 70\%$ attendance. Additionally, sensitivity analyses will be
530 performed using the per-protocol database and excluding participants who had injuries or other health
531 problems during the post-assessment evaluations. We will also analyze the effects of attendance and
532 compliance by conducting an analysis including individuals who, in addition to attending $\geq 70\%$ of the
533 sessions, also had $\geq 70\%$ compliance to the training protocol based on the time within the HIIT heart
534 rate target zones.

535 **2.10 Data management and sharing**

536 The HEART-BRAIN trial will use two data storage systems: (i) the REDCap platform, an online
537 software for the management of research databases in clinical trials and translational research. RedCap
538 will be used for the storage and management of all non-imaging information, guarantying its trace and
539 safety (34); (ii) the HEART-BRAIN desktop computer will also contain participants’ pseudonymized
540 data collected on paper-based forms, that will be scanned and stored, as well as the MRI data. Physical
541 copies of data collection forms and documents will be securely stored in a locked cabinet at the iMUDS
542 facility. Upon enrolment in the trial, participants will be assigned a unique code to be used consistently

543 across all forms and data collection reports, i.e. pseudonymized data, to reduce the risk of exposure
544 resulting from unintended unauthorized access or disclosure. In addition, information linking the
545 pseudonym to the identifiable information must be kept separately and subjected to ensure non-
546 attribution to an identified or identifiable individual. The PI will have access to the final dataset and
547 will provide reasonable and responsible access to the pseudonymized data to other researchers.
548 Participants will consent to the use of their pseudonymized data for secondary research, as outlined in
549 the informed consent process. Once a participant is enrolled, all data will undergo thorough quality
550 control checks and be archived following the storage protocol at iMUDS. Quality control measures
551 include visual inspection of imaging data, double correction of paper-pencil cognitive tests, and
552 verification of data validity and integrity in REDCap. The study will adhere to the FAIR principles
553 (Findability, Accessibility, Interoperability, and Reusability), and meta-data will be made publicly
554 available. A DOI (Digital Object Identifier) is issued to every published record. Governance, ethical
555 considerations, and shared trial oversight will be prioritized, aligning with current best practices. Study
556 results, including positive, negative, or inconclusive, will be disseminated through peer-reviewed
557 journals, and national and international conferences, and shared via social media and press releases
558 with participants, caregivers, physicians, and the broader medical and scientific community.

559 The protocol, statistical analyses plan and data management plan will be shared open access. Data files,
560 including pseudonymized individual participant data, will be shared under restricted access and upon
561 reasonable request (contact FBO) due to privacy issues and EU-GDPR regulations. In principle, all
562 collected individual participant data will be available for sharing under the "as open as possible, as
563 closed as necessary" principle. The shared data files will be pseudonymized, and only include
564 participants who provided informed consent for sharing, and sharing is only possible when the data is
565 used for research purposes related to exercise and cardiovascular and brain health. The individual
566 participant data will be available 12 months after the primary outcome paper is published. The specific

567 process of data access will be determined in a later stage. In short, data will be made available upon
568 reasonable requests to the PI (FBO). The data requests must contain the purpose and aim of the
569 research, target variables, and data analysis plan before data sharing. Data will only be shared for
570 research and public health purposes. A data access committee will be created to approve the appropriate
571 data requests. A data monitoring committee does not exist in the funding system in Spain.

572 **3 DISCUSSION**

573 CAD is associated with cognitive and mental health impairment (7-10). However, the mechanisms
574 explaining the connection between the heart and the brain in patients with CAD remain unknown (9).
575 Growing evidence supports the benefits of exercise on the cardiovascular health of individuals with
576 CAD (66-71). Yet, there is scarce knowledge on its influence on brain health. The mechanisms by
577 which different types of exercise might improve brain health or attenuate the cognitive and mental
578 health declines observed in patients with CAD remain to be elucidated. Well-designed intervention
579 studies unraveling the effects and mechanisms by which exercise impacts brain health in patients with
580 CAD will have important clinical and scientific implications. The findings will facilitate moving
581 towards a more ‘personalized medicine’ approach to exercise prescription in patients with CAD. Thus,
582 the present work provides a comprehensive description of the HEART-BRAIN RCT, following the
583 SPIRIT guidelines for interventional RCTs (30-32). The HEART-BRAIN project aims to examine the
584 effects of two different 12-week supervised exercise interventions (HIIT and HIIT combined with
585 resistance training) compared to usual care on brain and cardiovascular health in patients with CAD.
586 The primary outcome is CBF assessed by a cutting-edge technique called ASL-MRI.

587 Among the few studies that have evaluated the effects of exercise on brain health in individuals with
588 CAD, most of them have focused on health-related quality of life and mental health outcomes (72,

589 73). Other key domains of brain health such as cognition, biological markers of brain health, brain
590 morphology and function, or cerebrovascular outcomes remain unexplored.

591 This study will contribute to the advancement of scientific knowledge in different ways. Firstly, it
592 stands as an innovative intervention of two different exercise programs in accordance with the most
593 updated guidelines (23, 35, 50, 51). By providing a comprehensive description and pre-specified plan
594 of the study protocol, we ensure transparency and enable the scientific community to replicate the
595 protocols and intervention, fostering the dissemination of scientific knowledge. We expect that the
596 intervention and the obtained results will serve as a valuable resource for healthcare and exercise
597 professionals, allowing them to effectively prescribe individualized exercise to patients with CAD.
598 This represents an effective transfer of scientific knowledge to practical settings. This study
599 underscores the importance of systematic and well-defined methodological reports addressing the
600 transparency gaps within the scientific community and facilitating the comprehensive sharing of study
601 information.

602 **3.1 Strengths and limitations**

603 HEART-BRAIN has several strengths that bolster the reliability and validity of the expected results,
604 such as: i) well-designed RCT framework ensuring random allocation of participants, minimizing
605 selection bias, and enhancing the validity of the causal inferences drawn from the data; ii) extensive
606 brain health mapping, including comprehensive assessments of the different domains of brain health;
607 iii) comprehensive set of variables, including objective, gold-standard test (e.g., CPET) and patient-
608 reported outcomes (e.g., QoL) to encompass both physical and brain health; iv) continuous heart rate
609 monitoring throughout the exercise sessions allowing for a rigorous compliance analysis, v) time and
610 (estimated) caloric matched exercise groups, ensuring that any observed effects can be attributable to
611 the type of exercise rather than differences in exercise duration or intensity; vi) flexibility is offered to

612 help participants overcome barriers frequently reported about exercise participation (e.g., trainers adapt
613 to the time that fits best participants' schedule); vii) our mechanistic approach will provide insights on
614 how exercise can impact brain health in patients with CAD and the potential mechanisms explaining
615 the heart-brain connection, such as changes in CBF; and viii) this study holds significant clinical
616 relevance as it specifically targets potential improvements in brain health among patients with CAD, a
617 population known to experience accelerated cognitive decline.

618 The study also has some limitations that must be acknowledged. Since the HEART-BRAIN RCT is
619 implementing HIIT, certain criteria have been established to maximize safety. For example, only
620 individuals with a stable and controlled disease during the outpatient phase will be included. Future
621 trials recruiting a more generalizable group of patients with CAD (i.e., including individuals in a more
622 severe condition) are needed. Further, our study is of relative short duration (12 weeks). While notable
623 physiological changes may manifest within this timeframe, certain significant adaptations may require
624 a longer intervention and follow-up period. Although inherent to exercise-based RCTs, another
625 limitation is the single (and not double) blinding. These limitations should be taken into consideration
626 when interpreting the study's findings.

627 **4 Acknowledgments**

628 We thank Dr. Veronica Cabanas-Sanchez for performing the randomization of the study.

629 **5 Conflict of Interest**

630 The authors declare that the research is being conducted in the absence of any commercial or
631 financial relationships that could be construed as a potential conflict of interest.

632 **6 Author Contributions**

633 Conceptualization and project direction: FBO (principal investigator); Project coordination: AT;
634 Writing - original draft: AT, FBO; Writing - review & editing: AT, PSU, EAB, IMF, SVA, AC, IEC,
635 FBO. Formal analysis: EAB, PSU, FBO. All authors contributed intellectually to the design and
636 development of the methodology and approved the final manuscript of this study protocol. Our
637 authorship aligns with the ICMJE author contributions criteria (74).

638

639 **7 Funding**

640 The HEART-BRAIN Project is supported with the Grant PID2020-120249RB-I00 funded by
641 MCIN/AEI/10.13039/501100011033. Additional support was obtained from the Andalusian
642 Government (Junta de Andalucía, Plan Andaluz de Investigación, ref. P20_00124) and the CIBER de
643 Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Granada, Spain.
644 Moreover, EAB has received funding from the European Union’s Horizon 2020 research and
645 innovation programme under the Marie Skłodowska-Curie grant agreement No [101064851]. AT has
646 received funding from the Junta de Andalucía, Spain, under the Postdoctoral Research Fellows (Ref.
647 POSTDOC_21_00745). PS-U is supported by a “Margarita Salas” grant from the Spanish Ministry
648 Universities. IEC is supported by RYC2019-027287-I grant funded by
649 MCIN/AEI/10.13039/501100011033/ and “ESF Investing in your future”. IMF is supported by the
650 Spanish Ministry of Science, Innovation and Universities (JDC2022-049642-I). AC was funded by
651 postdoctoral research grants from the Swedish Heart-Lung Foundation (grant number 20230343), the
652 County Council of Ostergotland, Sweden (grant number RÖ-990967), the Swedish Society of
653 Cardiology, and the Swedish Society of Clinical Physiology. BFG is supported by the Spanish Ministry
654 of Education, Culture and Sport (PID2022-137399OB-I00) funded by
655 MCIN/AEI/10.13039/501100011033 and FSE+. MOR, LSA and JFO are supported by the Spanish
656 Ministry of Science, Innovation and Universities (FPU 22/02476, FPU 21/06192 and FPU 22/03052,
657 respectively). JHM is supported by the Spanish Ministry of Science, Innovation and Universities under
658 Beatriz Galindo’s 2022 fellowship program (BG22/00075). JSM is supported by the National Agency
659 for Research and Development (ANID)/Scholarship Program/DOCTORADO BECAS CHILE/2022–
660 (Grant N°72220164). SVA is supported by a Health and Behavior International Collaborative Award
661 by the Society of Behavioral Medicine. This work is part of a PhD thesis conducted in the Doctoral
662 Programme in Biomedicine of the University of Granada, Granada, Spain.

663 The sponsors or funding agencies had no role in the design and conduct of the study, in the collection,
664 analysis, and interpretation of data, in the preparation of the manuscript, or in the review or approval
665 of the manuscript.

666

667 **REFERENCES**

- 668 1. Stark B, Johnson C, Roth GA. Global prevalence of coronary artery disease: An update from
669 the global burden of disease study. *Journal of the American College of Cardiology*.
670 2024;83(13_Supplement):2320-.
- 671 2. WHO. Cardiovascular diseases (CVDs). World Health Organization; 2021 11 June 2021.
- 672 3. Tsao CW, Aday AW, Almarzooq ZI, Anderson CA, Arora P, Avery CL, et al. Heart disease
673 and stroke statistics—2023 update: a report from the American Heart Association. *Circulation*.
674 2023;147(8):e93-e621.
- 675 4. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European Society
676 of Cardiology: cardiovascular disease statistics 2021. *J European Heart Journal*. 2022;43(8):716-99.
- 677 5. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on
678 coronary artery disease, its risk factors, and therapeutics. *Journal of cellular physiology*.
679 2019;234(10):16812-23.
- 680 6. Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R, et al.
681 Economic burden of cardiovascular diseases in the European Union: a population-based cost study.
682 *Eur Heart J*. 2023;44(45):4752-67.
- 683 7. Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, et al. Depression
684 and coronary heart disease: 2018 position paper of the ESC working group on coronary
685 pathophysiology and microcirculation. *European heart journal*. 2020;41(17):1687-96.
- 686 8. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review
687 and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity
688 risk in coronary heart disease. *Journal of psychosomatic research*. 2014;77(6):439-48.
- 689 9. Roger VL. The heart–brain connection: from evidence to action. *European heart journal*.
690 2017;38(43):3229-31.
- 691 10. Schievink SH, van Boxtel MP, Deckers K, van Oostenbrugge RJ, Verhey FR, Köhler S.
692 Cognitive changes in prevalent and incident cardiovascular disease: a 12-year follow-up in the
693 Maastricht Aging Study (MAAS). *European heart journal*. 2022;43(7):e2-e9.
- 694 11. van Buchem MA, Biessels GJ, Brunner la Rocca HP, de Craen AJ, van der Flier WM, Ikram
695 MA, et al. The heart-brain connection: a multidisciplinary approach targeting a missing link in the
696 pathophysiology of vascular cognitive impairment. *Journal of Alzheimer's Disease*.
697 2014;42(s4):S443-S51.
- 698 12. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023
699 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic
700 Coronary Disease: A Report of the American Heart Association/American College of Cardiology
701 Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023;148(9):e9-e119.
- 702 13. Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-
703 based cardiac rehabilitation for coronary heart disease: a meta-analysis. *Eur Heart J*. 2023;44(6):452-
704 69.
- 705 14. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines
706 on sports cardiology and exercise in patients with cardiovascular disease. *Eur Heart J*. 2021;42(1):17-
707 96.

- 708 15. Sandercock G, Hurtado V, Cardoso F. Changes in cardiorespiratory fitness in cardiac
709 rehabilitation patients: a meta-analysis. *International journal of cardiology*. 2013;167(3):894-902.
- 710 16. Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological
711 modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. *Journal of*
712 *neuroscience research*. 2017;95(4):943-72.
- 713 17. Han H, Zhang R, Liu G, Qiao H, Chen Z, Liu Y, et al. Reduction of cerebral blood flow in
714 community-based adults with subclinical cerebrovascular atherosclerosis: A 3.0 T magnetic
715 resonance imaging study. *Neuroimage*. 2019;188:302-8.
- 716 18. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment
717 strategies. *Cell Metabolism*. 2019;179(2):312-39.
- 718 19. Rogers RL, Meyer JS, Mortel KF. After reaching retirement age physical activity sustains
719 cerebral perfusion and cognition. *Journal of the American Geriatrics Society*. 1990;38(2):123-8.
- 720 20. Swain RA, Harris AB, Wiener EC, Dutka MV, Morris HD, Theien BE, et al. Prolonged
721 exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the
722 rat. *Neuroscience*. 2003;117(4):1037-46.
- 723 21. Suzuki Y, Helle M, Koken P, Van Cauteren M, van Osch MJ. Simultaneous acquisition of
724 perfusion image and dynamic MR angiography using time-encoded pseudo-continuous ASL.
725 *Magnetic Resonance in Medicine*. 2018;79(5):2676-84.
- 726 22. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based
727 rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of
728 randomized controlled trials. *The American journal of medicine*. 2004;116(10):682-92.
- 729 23. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health
730 Organization 2020 guidelines on physical activity and sedentary behaviour. *British journal of sports*
731 *medicine*. 2020;54(24):1451-62.
- 732 24. Byrne RA, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
733 Guidelines for the management of acute coronary syndromes: Developed by the task force on the
734 management of acute coronary syndromes of the European Society of Cardiology (ESC). *J European*
735 *heart journal*. 2023;44(38):3720-826.
- 736 25. Committee PAGA. 2018 physical activity guidelines advisory committee scientific report. US
737 Department of Health and Human Services Washington, DC; 2018.
- 738 26. Lang JJ, Prince SA, Merucci K, Cadenas-Sanchez C, Chaput JP, Fraser BJ, et al.
739 Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among
740 adults: an overview of meta-analyses representing over 20.9 million observations from 199 unique
741 cohort studies. *British journal of sports medicine*. 2024.
- 742 27. Ross R, Blair SN, Arena R, Church TS, Després J-P, Franklin BA, et al. Importance of
743 assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a
744 scientific statement from the American Heart Association. *Circulation*. 2016;134(24):e653-e99.
- 745 28. Maleki S, Hendrikse J, Chye Y, Caeyenberghs K, Coxon JP, Oldham S, et al. Associations of
746 cardiorespiratory fitness and exercise with brain white matter in healthy adults: A systematic review
747 and meta-analysis. *Brain imaging and behavior*. 2022;16(5):2402-25.
- 748 29. Smith EC, Pizzey FK, Askew CD, Mielke GI, Ainslie PN, Coombes JS, et al. Effects of
749 cardiorespiratory fitness and exercise training on cerebrovascular blood flow and reactivity: a

- 750 systematic review with meta-analyses. *American journal of physiology Heart and circulatory*
751 *physiology*. 2021;321(1):H59-h76.
- 752 30. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT
753 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*.
754 2013;158(3):200-7.
- 755 31. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
756 explanation and elaboration: guidance for protocols of clinical trials. *Bmj*. 2013;346:e7586.
- 757 32. Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines
758 for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension. *JAMA cardiology*.
759 2022;328(23):2345-56.
- 760 33. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for
761 reporting parallel group randomised trials. *BMC medicine*. 2010;8:18.
- 762 34. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
763 consortium: building an international community of software platform partners. *Journal of*
764 *biomedical informatics*. 2019;95:103208.
- 765 35. Taylor JL, Holland DJ, Spathis JG, Beetham KS, Wisløff U, Keating SE, et al. Guidelines for
766 the delivery and monitoring of high intensity interval training in clinical populations. *Progress in*
767 *cardiovascular diseases*. 2019;62(2):140-6.
- 768 36. Morishita S, Tsubaki A, Nakamura M, Nashimoto S, Fu JB, Onishi H. Rating of perceived
769 exertion on resistance training in elderly subjects. *Expert review of cardiovascular therapy*.
770 2019;17(2):135-42.
- 771 37. Rognmo Ø, Moholdt T, Bakken H, Hole T, Mølstad P, Myhr NE, et al. Cardiovascular risk of
772 high-versus moderate-intensity aerobic exercise in coronary heart disease patients. *Circulation*.
773 2012;126(12):1436-40.
- 774 38. Wewege MA, Ahn D, Yu J, Liou K, Keech A. High-intensity interval training for patients
775 with cardiovascular disease—is it safe? A systematic review. *Journal of the American Heart*
776 *Association*. 2018;7(21):e009305.
- 777 39. Taylor JL, Holland DJ, Keating SE, Leveritt MD, Gomersall SR, Rowlands AV, et al. Short-
778 term and Long-term Feasibility, Safety, and Efficacy of High-Intensity Interval Training in Cardiac
779 Rehabilitation: The FITR Heart Study Randomized Clinical Trial. *JAMA Cardiol*. 2020;5(12):1382-
780 9.
- 781 40. Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, et al.
782 Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment
783 tool. *PloS one*. 2011;6(12):e28096.
- 784 41. Shah S. Common terminology criteria for adverse events. National Cancer Institute: USA.
785 2022.
- 786 42. Kilroy E, Apostolova L, Liu C, Yan L, Ringman J, Wang DJ. Reliability of two-dimensional
787 and three-dimensional pseudo-continuous arterial spin labeling perfusion MRI in elderly populations:
788 comparison with 15O-water positron emission tomography. *Journal of magnetic resonance imaging* :
789 *JMRI*. 2014;39(4):931-9.
- 790 43. Wang DJ, Alger JR, Qiao JX, Gunther M, Pope WB, Saver JL, et al. Multi-delay multi-
791 parametric arterial spin-labeled perfusion MRI in acute ischemic stroke - Comparison with dynamic
792 susceptibility contrast enhanced perfusion imaging. *NeuroImage Clinical*. 2013;3:1-7.

- 793 44. Ojeda N, del Pino R, Ibarretxe-Bilbao N, Schretlen D, Peña J. Test de evaluación cognitiva de
794 Montreal: normalización y estandarización de la prueba en población española. *Revista de*
795 *neurología*. 2016;63(11):488-96 % @ 0210-010.
- 796 45. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage.
797 *Perceptual and motor skills*. 1958;8(3):271-6 % @ 0031-5125.
- 798 46. Wechsler D. *WAIS-IV: Escala Wechsler de inteligencia para adultos-IV*. 2008.
- 799 47. Zelazo PD, Anderson JE, Richler J, Wallner-Allen K, Beaumont JL, Weintraub S. II. NIH
800 *Toolbox Cognition Battery (CB): measuring executive function and attention*. *Monogr Soc Res Child*
801 *Dev*. 2013;78(4):16-33.
- 802 48. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise training
803 increases size of hippocampus and improves memory. *Proc Natl Acad Sci U S A*. 2011;108(7):3017-
804 22.
- 805 49. Solis-Urra P, Molina-Hidalgo C, García-Rivero Y, Costa-Rodriguez C, Mora-Gonzalez J,
806 Fernandez-Gamez B, et al. Active Gains in brain Using Exercise During Aging (AGUEDA): protocol
807 for a randomized controlled trial. *Front Hum Neurosci*. 2023;17:1168549.
- 808 50. Bayles MP. *ACSM's exercise testing and prescription: Lippincott williams & wilkins*; 2023.
- 809 51. Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, et al. Aerobic exercise
810 intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the
811 European Association for Cardiovascular Prevention and Rehabilitation, the American Association of
812 Cardiovascular and Pulmonary Rehabilitation, and the Canadian Association of Cardiac
813 Rehabilitation. *Journal of cardiopulmonary rehabilitation and prevention*. 2012;32(6):327-50.
- 814 52. Shao X, Ma SJ, Casey M, D'Orazio L, Ringman JM, Wang DJJ. Mapping water exchange
815 across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. *Magn*
816 *Reson Med*. 2019;81(5):3065-79.
- 817 53. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018
818 *ESC/ESH Guidelines for the management of arterial hypertension*. *Eur Heart J*. 2018;39(33):3021-
819 104.
- 820 54. Langhammer B, Stanghelle JK. The Senior Fitness Test. *Journal of physiotherapy*.
821 2015;61(3):163.
- 822 55. Merellano-Navarro E, Collado-Mateo D, García-Rubio J, Gusi N, Olivares PR. Validity of
823 the International Fitness Scale "IFIS" in older adults. *Experimental gerontology*. 2017;95:77-81.
- 824 56. Izal M, Montorio I. Adaptation of the Geriatric Depression Scale in Spain: A preliminary
825 study. *Clinical Gerontologist*. 1993;13(2):83-91.
- 826 57. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta psychiatrica*
827 *Scandinavica*. 1983;67(6):361-70.
- 828 58. Remor E. Psychometric Properties of a European Spanish Version of the Perceived Stress
829 Scale (PSS). *The Spanish Journal of Psychology*. 2006;9(1):86-93.
- 830 59. Russell D, Peplau LA, Cutrona CE. The revised UCLA Loneliness Scale: concurrent and
831 discriminant validity evidence. *Journal of personality and social psychology*. 1980;39(3):472-80.
- 832 60. Robins R. Measuring global self-esteem: Construct validation of a single-item measure and
833 the Rosenberg self-esteem scale. *Personality Social Psychology Bulletin*. 2001;27:151-61.

- 834 61. Cutrona CE, Russell DW. The provisions of social relationships and adaptation to stress.
835 *Advances in personal relationships*. 1987;1(1):37-67.
- 836 62. Alonso J, Prieto L, Antó J. The Spanish version of the SF-36 Health Survey (the SF-36 health
837 questionnaire): an instrument for measuring clinical results. *Medicina clínica*. 1995;104(20):771-6.
- 838 63. Migueles JH, Rowlands AV, Huber F, Sabia S, van Hees VT. GGIR: a research community–
839 driven open source R package for generating physical activity and sleep outcomes from multi-day
840 raw accelerometer data. *Journal for the Measurement of Physical Behaviour*. 2019;2(3):188-96.
- 841 64. Troiano RP, Stamatakis E, Bull FC. How can global physical activity surveillance adapt to
842 evolving physical activity guidelines? Needs, challenges and future directions. *British journal of*
843 *sports medicine*. 2020;54(24):1468-73.
- 844 65. Li G, Taljaard M, Van den Heuvel ER, Levine MA, Cook DJ, Wells GA, et al. An
845 introduction to multiplicity issues in clinical trials: the what, why, when and how. *International*
846 *journal of epidemiology*. 2017;46(2):746-55.
- 847 66. Anderson L, Oldridge N, Thompson DR, Zwisler A-D, Rees K, Martin N, et al. Exercise-
848 Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-
849 Analysis. *Journal of the American College of Cardiology*. 2016;67(1):1-12.
- 850 67. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise
851 training modulates cytokines activity in coronary heart disease patients. *International Journal of*
852 *Cardiology*. 2005;100(1):93-9.
- 853 68. Niessner A, Richter B, Penka M, Steiner S, Strasser B, Ziegler S, et al. Endurance training
854 reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque
855 stabilization? *Atherosclerosis*. 2006;186(1):160-5.
- 856 69. Lavie CJ, Milani RV. Cardiac Rehabilitation and Exercise Training in Secondary Coronary
857 Heart Disease Prevention. *Progress in Cardiovascular Diseases*. 2011;53(6):397-403.
- 858 70. Pareja-Galeano H, Garatachea N, Lucia A. Exercise as a polypill for chronic diseases.
859 *Progress in Molecular Biology & Translational Science*
- 860 2015;135:497-526.
- 861 71. Muscella A, Stefano E, Marsigliante S. The effects of exercise training on lipid metabolism
862 and coronary heart disease. *American journal of physiology Heart and circulatory physiology*.
863 2020;319(1):H76-h88.
- 864 72. Gomes-Neto M, Duraes AR, Reis HFCd, Neves VR, Martinez BP, Carvalho VO. High-
865 intensity interval training versus moderate-intensity continuous training on exercise capacity and
866 quality of life in patients with coronary artery disease: A systematic review and meta-analysis. *J*
867 *European Journal of Preventive Cardiology*. 2017;24(16):1696-707.
- 868 73. Yu H, Zhao X, Wu X, Yang J, Wang J, Hou L. High-intensity interval training versus
869 moderate-intensity continuous training on patient quality of life in cardiovascular disease: a
870 systematic review and meta-analysis. *Scientific Reports*. 2023;13(1):13915.
- 871 74. Editors ICoMJ. Defining the role of authors and contributors. 2018.
- 872 75. Muñoz-García M, Cervantes S, Razquin C, Guillén-Grima F, Toledo JB, Martínez-González
873 M, et al. Validation study of a Spanish version of the modified Telephone Interview for Cognitive
874 Status (STICS-m). *Gaceta sanitaria*. 2019;33(5):415-20.

875 76. Brandt J, Spencer M, Folstein M. The Telephone Interview for Cognitive Status.
876 Neuropsychiatry, Neuropsychology, & Behavioral Neurology. 1988;1(2):111-7.

877

FIGURES AND TABLES

HEART-BRAIN TRIAL PARTICIPANTS FLOW




Figure 1. Visual representation of the study design in the HEART-BRAIN trial. ACC: Accelerometry; CAD: coronary artery disease; CPET: cardiopulmonary exercise test; ECO: echography; COG; cognitive function tests; MRI: magnetic resonance imaging UC: usual care. *Post-intervention assessment includes similar outcomes compared to baseline assessment.

Table 1. HEART-BRAIN inclusion and exclusion criteria for selecting participants.

INCLUSION CRITERIA:

1. Men and women aged 50 - 75 years old, both inclusive (*Contingency plan: increase the range to 40-75 if we have difficulties to get the study sample)
2. Must have stable coronary artery disease (phase III), proven by invasive coronary angiography or CT with at least one coronary stenosis with > 50% luminal reduction.
3. Able to speak and read fluent Spanish.
4. Living in Granada city or surrounding areas (able to come to evaluations and exercise program)
5. Living in the community during the study (i.e. independent home, non-assisted living facilities)
6. Left ventricular ejection fraction \geq 45%, determined by echocardiography
7. Functional grade I-II according to the New York Heart Association (NYHA) scale.
8. Sinus rhythm.
9. Stable optimal medical treatment (determined by a cardiologist).
10. Physically inactive, considering: 1) not meeting the WHO recommendations in neither the aerobic nor strength part, and 2) not participating in a planned and structured exercise program at least 3 days per week for the last 3 months. Both conditions must be met to be included and will be ascertained during a screening phone call. Note: going for a walk will not be considered an exclusion reason.
11. No signs of manifest cognitive disorder according to the Spanish Telephone Interview for Cognitive Status-modified (STICS-m) scoring of 26 and above (75, 76).

EXCLUSION CRITERIA:

1. Use of assisted walking devices.
2. Acute coronary syndrome in the last year.
3. Coronary artery by-pass surgery or percutaneous intervention in the last 6 months.
4. Treatment for any type of cancer in the last 2 years.
5. Hospitalization in the intensive care unit in the last 6 months.
6. Current psychiatric diagnosis (visit to psychiatrist and drug treatment prescription in the last year), including major depression and history of psychiatric illness (schizophrenia, bipolar disorder, hallucinations).
7. Grade III obesity (BMI > 40).
8. Diagnosis of neurological or cerebrovascular disorder (e.g., stroke).
9. Medical contraindication for inclusion in an exercise program.
10. Diabetes with uncontrolled hyperglycemia.
11. Resting blood pressure > 180/110 mmHg.
12. Exercise-induced chest pain or changes in the ST segment suggestive of severe ischemia during exercise testing
13. Severe inducible ischemia
14. Low functional capacity in ergometry (<5 METS).
15. Obstructive left main artery disease (significant disease > 50% obstruction)
16. Unstable angina
17. Uncontrolled cardiac arrhythmia
18. Presence of metal implants (e.g., pacemaker or implantable cardioverter-defibrillator-ICD) not compatible with MRI (reported during the phone screening)

19. Paroxysmal or persistent atrial fibrillation with episodes in the last 6 months.
20. Moderate to severe pulmonary hypertension.
21. Acute endocarditis, myocarditis, or pericarditis.
22. Moderate to severe heart valve disease (grade 3-4)
23. Acute pulmonary embolism, or deep vein thrombosis.
24. Aortic dissection
25. High-grade heart block or complete left bundle branch block or altered basal electrocardiogram with difficulties to interpret in exercise testing.
26. Hypertrophic obstructive cardiomyopathy.
27. Retinopathy.
28. Severe autonomic or peripheral neuropathy.
29. Acute systemic illness or fever.
30. Acute or chronic renal failure (estimated glomerular filtration rate < 30 mL/min)
31. Pulmonary fibrosis or interstitial disease (respiratory failure or severe COPD confirmed by pneumological study).
32. Recent treatment for alcohol or substance abuse.
33. Claustrophobia.
34. Any surgery or medical intervention planned during the study period.
35. Plans to participate or current participation in other studies that might interfere with this study.
36. Current pregnancy or intention to get pregnant during the study period.

CT: computer tomography; METS: metabolic equivalent; COPD: Chronic obstructive pulmonary disease

Table 2. Outcomes instruments and time points of data collection.

Outcomes	Instrument / Tool	Pre	Mid	Post
PRIMARY OUTCOME				
Cerebral blood flow	MRI: turbo gradient spin echo-pseudo continuous arterial spin labeling	x		x
SECONDARY OUTCOMES				
Cerebral vascularization	MRA: Time-of-flight angiography	x		x
Executive function	Desing Substitution Symbol Test; Trail Making Test; Spatial Working Memory Test (E-prime); Dimensional Card Sort Test; Flanker Test; Picture Sequence Test; and List Sort Working Memory Test	x		x
General cognition	Montreal Cognitive Assessment test (MOCA)	x		x
Cardiorespiratory fitness	Treadmill Cardiorespiratory exercise test with gas exchange analysis	x		x
OTHER OUTCOMES				
Brain structure and function				
Blood brain barrier permeability	MRI: 3D diffusion-prepared arterial spin labelled perfusion	x		x
Brain morphology	MRI: T1-weighted MPRAGE structural	x		x
White matter structure	MRI: Diffusion weighted acquisition	x		x
Brain function	Functional MRI: Resting state echo planar imaging	x		x
Biological samples				
Neurology biomarkers				
Inflammatory biomarkers	Blood and saliva samples (type of analysis to be determinate with the best method available at moment of analysis)	x		x
Cardiovascular biomarkers	Blood samples (type of analysis to be determinate with the best method available at moment of analysis)	x		x
Gene expression and epigenetics	Genetic analysis in blood and saliva samples (qRT-PCR and others to be determinate with the best method available at moment of analysis)	x		x
Oral and gut microbiota	Saliva and fecal samples	x		x
Hemodynamics				
Vascular hemodynamics	Carotid ultrasound	x		x
Cardiac hemodynamics	Echocardiography	x		x
Transcranial hemodynamics	Transcranial ultrasound	x		x
Blood pressure	Blood pressure monitor	x		x
Arterial stiffness	Carotid-femoral pulse wave velocity, SphygmoCor XCEL	x		x
Physical functioning and body composition				
Muscle strength	Chair stand test, arm curl test and hand dynamometer TKK 5101	x		x
Physical function	Senior Fitness Test and 6-min walking test	x		x
Body composition	Dual-energy x-ray absorptiometer (DXA) and a TANITA's Bioelectrical Impedance Analysis	x		x
Mental health and behaviour				
Depression	Hospital Anxiety and Depression Scale	x		x
Anxiety	Hospital Anxiety and Depression Scale	x		x
Stress	Perceived Stress Scale	x		x
Loneliness	UCLA Loneliness Scale	x		x

Self-esteem	Rosenberg Self-Esteem Scale	x		x
Social support	Social Provisions Scale	x		x
Health-related quality of life	Health Survey Short Form (SF-36)	x		x
Physical activity	Accelerometer Axivity AX (pre and mid), and a self-reported questionnaire based on the Global Physical Activity Questionnaire	x	x	
Sedentary behavior	Accelerometer Axivity AX (pre and mid), and a self-reported questionnaire based on the Global Physical Activity Questionnaire	x	x	
Sleep duration and quality	Accelerometer Axivity AX (pre and mid) and a self-reported questionnaire	x	x	
Diet behavior	14-item Questionnaire of Mediterranean Diet Adherence, and self-reported question for supplements	x	x	x

DESCRIPTIVES OR COVARIATES FOR ANALYSES

Educational level
 Ethnicity
 Smoking habits
 Alcohol consumption
 Medication
 Comorbidities (e.g., dyslipidemia, hypertension, type 2 diabetes)
 Family history of dementia
 Handedness
 COVID-19 history
 Genotyping of APOE, BDNF and others

Pre: baseline assessments; mid: assessments at 6 weeks; post: assessments at 12 weeks, just after finish intervention MRI: magnetic resonance imaging; qRT-PCR: quantitative real-time polymerase chain reaction; APOE: Apolipoprotein E; BDNF: Brain-Derived Neurotrophic Factor.

Table 3. Brain Magnetic Resonance Imaging (MRI) parameters of the HEART-BRAIN trial

SEQUENCE	PARAMETERS	OUTCOMES	ACQUISITION TIME (MIN)
TOF (Time of flight angiography)	TR=21 ms, TE=3.43 ms, Flip angle: 18grad., FOV=200 mm, acquisition bandwidth of 155 Hz/PX, 44 slices (18.2% oversampling), resolution = 0.3×0.3×0.8 mm ³	Angiography (cerebral vascularization)	8
T1-weighted MPRAGE structural	Sagittal, 0.8 mm isotropic resolution, TE/TI/TR = 2.31/1060/2400 ms, FOV = 256 mm, 224 slices	Brain structure	6
diffusion-prepared pCASL (DP-pCASL) sequence	TR = 4 sec, TE = 36.5 ms, FOV = 224 mm, matrix size = 64×64, 12 slices (10% oversampling), resolution = 3.5×3.5×8 mm ³ , label/control duration = 1500 ms, centric ordering, and optimized timing of background suppression for gray matter (GM) and white matter (WM)	Blood brain barrier permeability	10
Resting state EPI	Resolution: 2.5 × 2.5 × 2.5 mm, TE/TR = 40/1000 ms, Multiband factor = 8 (CMRR EPI sequence), 64 slices, 480 measurements	Resting BOLD (Blood Oxygen Level Dependent)	5
Diffusion weighted acquisition	Resolution: 2 × 2 × 2 mm, TE/TR = 95.6/2800 ms, Multiband factor = 4, b-values of 1500, 3000 s/mm ² , 64 gradient directions	White matter microstructure	8
pCASL TGSE	3D GRASE pCASL sequence, Resolution: 3.1 × 3.1 × 2.5 mm, TE/TR = 23.64/4300 ms, 48 slices, Multiple Post-labeling delay [0.5, 0.5, 1, 1, 1.5, 1.5, 2.0, 2.0, 2.0 s], Background Suppression, 9 measurements for labeling and control, 4 segment readout	Cerebral blood flow	6
MRI-Abdominal	Resolution: 2 × 2 × 2 mm, TE1-2/TR = 1.23-2.46/5.21 ms, flip angle 9°, CAIPIRINHA iPAT factor = 4, FOV = 448 mm	Visceral adipose tissue	5

FOV: Field of View; Hz: hertz; PX: pixel; MPRAGE: Magnetization Prepared Rapid Gradient Echo; pCASL: pseudo-Continuous Arterial Spin Labelling; TE: Echo Time; TI: Inversion Time; TR: Repetition Time; EPI: Echo Planar Imaging; TGSE: Turbo Gradient Spin-Echo

Table 4. Cognitive tests included in the HEART-BRAIN trial.

Cognitive test	Day / session	Format	Domain	Time
Spanish Telephone Interview for Cognitive Status (75, 76)	Telephone screening	Verbal	General cognition	10 min
Montreal Cognitive Assessment (44)	2	Verbal-paper-pencil	General cognition	10 min
Trail Making Test A and B (45)	2	Paper-pencil	Executive function: Cognitive flexibility	5 min
Digit Symbol Substitution Test (46)	2	Paper-pencil	Processing speed and attention	5 min
Dimensional Change Card Sort Test (47)	1	Computerized	Executive function: Cognitive flexibility and inhibition	5 min
List Sorting Working Memory Test (47)	1	Computerized	Executive function: Working memory (verbal)	5 min
Flanker Test (47)	1	Computerized	Executive function: inhibitory control and attention	5 min
Spatial Working Memory Test (48)	3	Computerized	Executive function: Working memory (spatial)	10 min
Picture Sequence Memory Test (47)	1	Computerized	Episodic memory	5 min

Table 5. Biological samples and targeted analysis plan

SAMPLE	ANALYSIS TARGET	PRELIMINARY ANALYSIS PLAN
Blood samples		
Plasma	A β (Amyloid beta) peptides A β 1-42, A β 1-40; BD-tau and P-tau; Neurofilament light chain (NFL); Glial fibrillary acidic protein (GFAP); Vascular endothelial growth factor (VEGF); chemokine C-X-C motif ligand 13 (CXCL-13); IgM-1; IL-17; pancreatic polypeptide (PPY); Adiponectin; Brain-derived neurotrophic factor (BDNF); Cathepsin B; vascular cell adhesion molecule 1 (VACM-1); C-reactive protein (CRP); high-sensitivity CRP; Interleukin-6 (IL-6); Interleukin-17 (IL-17); Tumor necrosis factor (TNF-Alpha); Klotho; GLP-1, Clusterin	Plasma biomarker Ab (Amyloid beta) peptides Ab1-42, Ab1-40; BD-tau and P-tau; Neurofilament light chain - NFL GFAP- concentrations will be measured using Single molecule array (Simoa) methods on an HD-X instrument and commercial assays from Quanterix. Key inflammatory biomarkers will be analyzed with automated blood cell counters and quantified by multiple analyte profiling technology (MILLIPLEX R MAP Human High Sensitivity T-Cell Magnetic Bead Panel, EMD Millipore Corporation, Missouri, U.S.A.) Klotho will be determined using a solid-phase sandwich enzyme-linked immunosorbent assay (Demeditec, Kiel, Germany) according to the manufacturer's protocol.
Peripheral Blood Mononuclear Cells	Telomere length	A commercial DNA isolation kit (Qiagen, Barcelona, Spain) will be used to extract genomic DNA from isolated PBMCs. Relative telomere length will be determined by quantitative real-time polymerase chain reaction (qRT-PCR) using the telomere/single-copy gene ratio (T/S)
Serum	Insulin-like growth factor 1 (IGF-1); Insulin; Glucose; Glycated Hemoglobin (HbA1c), creatinine, Serum fatty acid (SFA-1), total, HDL and LDL cholesterol, glomerular filtration rate, triglycerides	IGF-1, insulin, glucose, glycated hemoglobin (HbA1c) and serum fatty acids (SFA-1) will be analyzed using XMap technology (Luminex Corporation, Austin, TX) and human monoclonal antibodies (Milliplex Map Kit; Millipore, Billerica, MA). Total cholesterol, HDL-C, LDL-C, triglycerides, and glucose will be assessed using a spectrophotometer. Insulin will be assessed by chemiluminescence immunoassay.
Whole Blood	Glycated hemoglobin (A1c), RNA and DNA analyses	Blood specimens will be used for genotyping. The genotypes will be determined using TaqMan genotyping assays (e.g., APOE). A commercial RNA isolation kit (Qiagen, Barcelona, Spain) will be used to extract total RNA from whole blood samples. The selection of specific miRNAs will be based on the existing bibliographic information. In accordance with this, the selected miRNA will be evaluated using Taqman probes.
Saliva samples	Oral microbiota and other potential biomarkers	To be determined with the best method available at the moment of analysis
Fecal samples	Metagenomic Analysis of the Gut Microbiome	To be determined with the best method available at the moment of analysis